• Current glaucoma treatments face challenges in achieving sustained drug release & maintaining consistent Intraocular Pressure (IOP) Control.
• Conventional eye drops may result in limited bioavailability and patient compliance, leading to suboptimal treatment outcomes.
• There is a need for innovative drug delivery systems that can provide controlled & prolonged drug release for better glaucoma management while minimizing the side effects & increasing the patient adherence.
• The instant patent addresses the above given issues by disclosing a process for preparation of nanoparticles for fixed combination Monotherapy.

• The present patent discloses Nanoparticles and the Process for Fixed Combination Monotherapy.
• This patent is about using small particles to deliver drugs for treating glaucoma.
• These particles have a unique structure that allows for controlled drug release. Special materials and methods are used to enhance treatment effectiveness, and Betacyclodextrin is used to improve drug absorption in the eyes.

It is a process to create tiny drug-delivery particles with a core and shell for better eye treatment.

• Nanoparticle Creation: The process begins by making tiny core-shell nanoparticles.
• Core Solution: A mixture is made for the core. It includes a polymer, a drug, and a liquid (acetonitrile).
• Shell Solution: Another mixture is created for the shell. It has a polymer, a drug, and a mix of liquids.
• The core and shell mixtures are sprayed through a special needle with high voltage, to small particles.
• Collecting and Drying: These particles are collected on a metal plate, then dried to fine powder.
• Functionalization: The drug-carrying powder is mixed with a substance to help it penetrate the eyes better.
• Freeze-Drying: The final product, spherical nanoparticles, is made by freeze-drying.